目的 探讨冠心宁注射液联合替格瑞洛片治疗ST段抬高型心肌梗死的临床疗效。方法 选取2017年6月-2018年6月在义马煤业集团股份有限公司总医院治疗的ST段抬高型心肌梗死患者82例作为研究对象，根据用药的不同将患者分为对照组（41例）和治疗组（41例）。对照组口服替格瑞洛片，起始剂量为180 mg/次，此后90 mg/次，2次/d；治疗组在对照组治疗的基础上静脉滴注冠心宁注射液，20 mL加入5%葡萄糖注射液500 mL中，1次/d。两组患者均治疗1周。观察两组患者的临床疗效，比较两组治疗前后的中医证候积分、SF-36量表评分、心功能指标和血清学指标。结果 治疗后，对照组和治疗组总有效率分别为80.49%、97.56%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组中医证候积分明显降低，SF-36量表评分明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组中医证候积分、SF-36量表评分显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组左心室射血分数（LVEF）显著升高，左心室收缩末内径（LVESD）、左室舒张末期内径（LVEDD）和左心室收缩末期容积（LVESV）均明显降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组患者心功能指标显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清B型利钠肽（BNP）、单核细胞趋化蛋白-1（MCP-1）、白细胞介素-1β（IL-1β）、肌钙蛋白（cTnT）、肌酸激酶同工酶（CK-MB）和基质金属蛋白酶-9（MMP-9）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清学指标水平均显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 冠心宁注射液联合替格瑞洛片治疗ST段抬高型心肌梗死具有较好的临床疗效，可提高患者生活质量，改善心功能，显著降低机体炎症因子，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Guanxinning Injection combined with Ticagrelor Tablets in treatment of ST segment elevation myocardial infarction. Methods Patients (82 cases) with ST segment elevation myocardial infarction in The General Hospital of Yima Coal Industry Group Co. Ltd from June 2017 to June 2018 were divided into control (41 cases) and treatment (41 cases) groups according to the medication. Patients in the control group were po administered with Ticagrelor Tablets, initial dose was 180 mg/time, and then 90 mg/time, twice daily. Patients in the treatment group were iv administered with Guanxinning Injection on the basis of the control group, 20 mL added into 5% glucose injection 500 mL, once daily. Patients in two groups were treated for 1 week. After treatment, the clinical efficacy was evaluated, and the TCM syndrome scores, SF-36 scores, cardiac function indexes, and serological indicators before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.49% and 97.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, TCM syndrome scores in two groups were significantly decreased, but SF-36 scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, TCM syndrome scores and SF-36 scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, LVEF in two groups were significantly increased, but LVESD, LVEDD, and LVESV in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of BNP, MCP-1, IL-1β, cTnI, CK-MB, and MMP-9 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the levels of serological indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Guanxinning Injection combined with Ticagrelor Tablets has good clinical efficacy in treatment of ST segment elevation myocardial infarction, can improve the quality of life and cardiac function of patients, and significantly reduce inflammatory factors, which has a certain clinical application value.